Activation of FCGR2A enhances the antitumor efficacy of hPSC-derived CAR-M.

ABSTRACT:

Introduction

Chimeric antigen receptor macrophages (CAR-Ms) represent a novel approach in cellular immunotherapy. Human pluripotent stem cells (hPSCs) provide an unlimited and renewable cell source, enabling scalable and standardized production of CAR-Ms with consistent quality.

Methods

In this study, we established a robust differentiation protocol to generate CAR-Ms from hPSCs. To evaluate HER2-directed hPSC-derived CAR-M functionality, we first profiled HER2 expression across multiple tumor cell lines and identified SKOV3 as the optimal target due to its high HER2 level. CAR constructs incorporating intracellular domains from CD3ɛ, FCGR1A, FCGR2A, FCGR2B, and FCGR3A were introduced into hPSCs via lentiviral transduction.

Results

Importantly, CAR expression did not

SUBMITTER: Yang X 

PROVIDER: S-EPMC12833421 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature